Anthropic has set targets to raise up to $100 billion at a $1.5 trillion valuation, scheduling an investor roadshow for the week of November 9 ahead of a November debut. However, institutional investors view that price tag as excessively expensive, suggesting a drop toward $1 trillion may be necessary to attract sufficient demand. Beyond market turbulence, the company is navigating scrutiny over its heavy financial losses, surging infrastructure commitments, and reliance on external cloud partners.
Key points
Widespread declines in tech shares and AI infrastructure firms are jeopardizing the plann…: Widespread declines in tech shares and AI infrastructure firms are jeopardizing the planned timing of the November listing.
Lingering skepticism over massive, ongoing data center investments is eroding investor wi…: Lingering skepticism over massive, ongoing data center investments is eroding investor willingness to accept premium AI valuations.
A postponement or reduced offering price could amplify broader industry concerns regardin…: A postponement or reduced offering price could amplify broader industry concerns regarding the financial sustainability of artificial intelligence.
Sources checked by our analysis pipeline: 1
Anthropic's proposed IPO is facing growing investor resistance amid a sharp selloff in technology stocks. Investors are questioning whether the AI startup can proceed with its planned November listing at a $1.5 trillion valuation, with a possible delay also emerging as an option, Reuters reported. (Sources: Reuters, Investing.com, Financial Express)
Agencies
2/6
Investors push for valuation cut
The proposed $1.5 trillion valuation is increasingly being viewed as expensive by institutional investors. According to a Wall Street Journal report cited by Investing.com and Financial Express, some investors believe the valuation may need to fall closer to $1 trillion to attract sufficient demand.
Agencies
3/6
$100 billion IPO ambition at risk
Anthropic was targeting an IPO that could raise as much as $100 billion, potentially making it one of the largest stock market listings ever. The company had been preparing to begin its investor roadshow in the week of November 9, with a November listing in sight. However, market volatility could force a reassessment of the timeline.
Clinical documentation frequently excludes critical aspects of care experienced by female patients, creating severe blind spots for automated healthcare models. When patient dismissals, misdiagnoses, and symptoms filtered through clinician bias are omitted from official charts, machine-learning algorithms ingest a skewed record of treatment history. This data shortfall threatens to entrench systemic oversights into automated transcription, summarization, and diagnostic support systems.
Speaking at the FT's Future of AI Summit, the Microsoft co-founder warned that bad actors could leverage advanced technologies to unleash catastrophic cyberattacks or engineer pandemics far worse than Covid-19. Without federal cooperation, global safeguards remain stalled while self-regulation by tech companies falls short. He argued that global leaders remain profoundly unprepared for the mounting threats to labor markets, biosecurity, and international stability.
Washington is reevaluating its regulatory approach toward the artificial intelligence sector amid shifting political dynamics. Industry experts are closely watching to determine if emerging federal oversight will hinder the pace of technological innovation. Despite these policy uncertainties, leading technology firms are continuing to allocate unprecedented financial capital to build out critical infrastructure.